DEFLAZACORT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H31NO6
Molecular Weight	441.5167
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O

InChI

InChIKey=FBHSPRKOSMHSIF-GRMWVWQJSA-N

InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H31NO6
Molecular Weight	441.5167
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by suppressing inflammatory response.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
inflammatory response 47	Inhibitor 8,297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Immune system diseases 2	Primary		Approved 8,429	CALCORT

C_max

Value	Dose	Co-administered	Analyte	Population
381 ng/mL	0.9 mg/kg single, oral		21-DESACETYLDEFLAZACORT plasma	Homo sapiens
206 ng/mL	0.9 mg/kg single, oral		21-DESACETYLDEFLAZACORT plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
655 ng × h/mL	0.9 mg/kg single, oral		21-DESACETYLDEFLAZACORT plasma	Homo sapiens
400 ng × h/mL	0.9 mg/kg single, oral		21-DESACETYLDEFLAZACORT plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
60%	0.9 mg/kg single, oral		21-DESACETYLDEFLAZACORT plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
1.2 mg/kg 1 times / day multiple, oral Higher than recommended	unhealthy, 5 - 15 years	Other AEs: Cushingoid, Erythema...
0.9 mg/kg 1 times / day multiple, oral Recommended	unhealthy, 5 - 15 years n = 51	Other AEs: Cushingoid, Weight increased...
0.9 mg/kg 1 times / day multiple, oral Recommended	unhealthy, 5 - 15 years n = 51	Other AEs: Cushingoid, Hirsutism...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Acne	11%	1.2 mg/kg 1 times / day multiple, oral Higher than recommended	unhealthy, 5 - 15 years
Skin striae	11%	1.2 mg/kg 1 times / day multiple, oral Higher than recommended	unhealthy, 5 - 15 years
Abdominal pain upper	14%	1.2 mg/kg 1 times / day multiple, oral Higher than recommended	unhealthy, 5 - 15 years
Constipation	15%	1.2 mg/kg 1 times / day multiple, oral Higher than recommended	unhealthy, 5 - 15 years
Weight increased	32%	1.2 mg/kg 1 times / day multiple, oral Higher than recommended	unhealthy, 5 - 15 years

Showing 1 to 5 of 41 entries

Previous1 2 3 4 5…9Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1,737 inhibitor 1,587 inducer 781	inhibitor 1,767	inhibitor 1,852	inhibitor 1,612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1,524 CYP2C19 1,478 UGT1A1 204 UGT1A4 77 UGT1A6 108 UGT1A9 116 UGT2B7 146 CYP2B6 810 CYP2C8 911 UGT1A3 84 UGT2B15 64 P-gp 1,461 BCRP 699 OATP1B1 788 OATP1B3 706 OAT1 599 OAT3 642 OCT2 647	esterase 72 P-gp 1,537 BCRP 561 OATP1B1 406 OATP1B3 350	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Show entries

Target	Modality	Activity	Metabolite
BCRP 773	inhibitor 3,277	no	21-DESACETYLDEFLAZACORT 2
CYP1A2 1,692	inducer 1,573	no	21-DESACETYLDEFLAZACORT 2
CYP1A2 1,692	inhibitor 3,277	no	21-DESACETYLDEFLAZACORT 2
CYP2B6 1,001	inducer 1,573	no	21-DESACETYLDEFLAZACORT 2
CYP2C19 1,553	inhibitor 3,277	no	21-DESACETYLDEFLAZACORT 2

Showing 1 to 5 of 24 entries

Previous1 2 3 4 5Next

Drug as victim

Show entries

Target	Modality	Activity	Metabolite
BCRP 561	substrate 3,367	no	21-DESACETYLDEFLAZACORT 2
OATP1B1 406	substrate 3,367	no	21-DESACETYLDEFLAZACORT 2
OATP1B3 350	substrate 3,367	no	21-DESACETYLDEFLAZACORT 2
P-gp 1,537	substrate 3,367	yes	21-DESACETYLDEFLAZACORT 2
esterase 72	substrate 3,367	yes

Showing 1 to 5 of 6 entries

Previous1 2Next

Tox targets

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1,647	inhibitor 1,626		21-DESACETYLDEFLAZACORT 2

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Prednisone versus deflazacort in the treatment of autoimmune thrombocytopenic purpura: evaluation of clinical response and immunological modifications.	1991 Jul-Aug	1794742
Effectiveness of nifedipine and deflazacort in the management of distal ureter stones.	2000 Oct 1	11018608
Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties.	2004 Sep	15362971

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose for most conditions, including rheumatoid arthritis is half to three tablets each day, the dose for severe asthma may be up to 8 or 12 tablets each day.

Route of Administration: Oral

In Vitro Use Guide

Phytohaemagglutinin stimulated peripheral blood lymphocytes, NK and K cells were incubated with different concentrations of the drug (0, 1.2, 6.0, 24, 60, 240, and 600 x 10(-7) M) and the immunosuppressive effect was measured. Deflazacort suppressed the cells in a dose dependent way.

Substance Class	Chemical
Record UNII	KR5YZ6AE4B
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

DEFLAZACORT

Official Name

English

EMFLAZA

Brand Name

English

DEFLAZACORT [USP-RS]

Common Name

English

11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATE

Common Name

English

DEFLAZACORT [MI]

Common Name

English

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Therapeutic Corticosteroid

NCI_THESAURUS

C521

Designated/Withdrawn

FDA ORPHAN DRUG

491715

Designated

FDA ORPHAN DRUG

315110

Glucocorticoids

WHO-VATC

QH02AB13

Designated/Approved

FDA ORPHAN DRUG

403413

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

LACTMED

Deflazacort

PRIMARY

MERCK INDEX

m4135

PRIMARY

Merck Index

EPA CompTox

DTXSID9020378

PRIMARY

RS_ITEM_NUM

1166116

PRIMARY

ECHA (EC/EINECS)

238-483-7

PRIMARY

Showing 1 to 5 of 20 entries

Previous1 2 3 4Next

Show entries

Related Record

Type

Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:

40 % (average)


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					FZW85LW99M

GLUCOCORTICOID RECEPTOR

TARGET -> INHIBITOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INHIBITOR

Comments:

- Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. - Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ.

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details